Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer

Cancer

Volumn 116, Issue 13, 2010, Pages 3276-3284

  Annunziata, Christina M ^a   Stavnes, Helene Tuft ^b   Kleinberg, Lilach ^b   Berner, Aasmund ^b   Hernandez, Lidia F ^a   Birrer, Michael J ^c   Steinberg, Seth M ^a   Davidson, Ben ^b,d   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Immunohistochemistry; Matrix metalloproteinase 9; Nuclear factor B; Ovarian cancer; P50; Prognosis; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; GELATINASE B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN P50; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELB; ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TREATMENT OUTCOME;

EID: 77954297744     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25190     Document Type: Article

References (28)

1. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-436. (Pubitemid 44050137)
2. Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007;13:3423-3430.
3. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859-3868.
4. Liu GH, Wang SR, Wang B, Kong BH. Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer. 2006;16:1777-1782. (Pubitemid 44470035)
5. Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT, Sarkar FH. Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB [serial online]. J Ovarian Res. 2008;1:9.
6. Brown M, Cohen J, Arun P, Chen Z, Van Waes C. NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets. 2008;12:1109-1122.
7. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 2005;23:5943-5949.
8. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817-6830.
9. Yan C, Wang H, Aggarwal B, Boyd DD. A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NF-kappaB motif drives the transition from a repressed to an activated state of gene expression. FASEB J. 2004;18:540-541.
10. Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008;6:525-534. (Pubitemid 351521834)
11. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939-944.
12. Sarosy GA, Hussain MM, Seiden MV, et al. Ten-year follow up of a phase 2 study of does-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poorprognosis, advanced stage epithelial ovarian cancer. Cancer. 2010;116:1476-1484
13. Hussain MM, Seiden MV, Fuller A, et al. A two institution phase II study of paclitaxel (T), cyclophosphamide (C), cisplatin (P) with G-CSF (G) for patients with newly diagnosed advanced stage ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21. Abstract 813.
14. Kohn EC, Sarosy GA, Davis P, et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol. 1996;62:181-191.
15. Hollander M, Wolfe D. Nonparametrical Statistical Methods. 2nd ed. New York: John Wiley & Sons, Inc.; 1999.
16. Agresti A. Categorical Data Analysis. New York: John Wiley & Sons, Inc.; 1990.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chem Rep. 1966;50:163-170.
19. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
20. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353-357.
21. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68:5478-5486.
22. Annunziata CM, Kleinberg L, Davidson B, et al. BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res. 2007;13(22 pt 1):6585-6592. (Pubitemid 350206792)
23. Slipicevic A, Oy GF, Askildt IC, et al. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol. 2009;40:527-537.
24. Sillanpaa S, Anttila M, Voutilainen K, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 2007;104:296-303.
25. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007;6:11.
26. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther. 2008;7:3441-3451.
27. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9-34.
28. Saccani A, Schioppa T, Porta C, et al. p50 Nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66:11432-11440. (Pubitemid 46009975)